Does the media refer more to ALNY or GILD?

In the previous week, Gilead Sciences had 12 more articles in the media than Alnylam Pharmaceuticals. MarketBeat recorded 36 mentions for Gilead Sciences and 24 mentions for Alnylam Pharmaceuticals. Gilead Sciences' average media sentiment score of 0.86 beat Alnylam Pharmaceuticals' score of 0.37 indicating that Gilead Sciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alnylam Pharmaceuticals 6 Very Positive mention(s) 1 Positive mention(s) 9 Neutral mention(s) 4 Negative mention(s) 1 Very Negative mention(s) Neutral Gilead Sciences 22 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 5 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor VRTX or ALNY?

In the previous week, Vertex Pharmaceuticals had 32 more articles in the media than Alnylam Pharmaceuticals. MarketBeat recorded 56 mentions for Vertex Pharmaceuticals and 24 mentions for Alnylam Pharmaceuticals. Vertex Pharmaceuticals' average media sentiment score of 0.80 beat Alnylam Pharmaceuticals' score of 0.37 indicating that Vertex Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vertex Pharmaceuticals 31 Very Positive mention(s) 10 Positive mention(s) 12 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Alnylam Pharmaceuticals 6 Very Positive mention(s) 1 Positive mention(s) 9 Neutral mention(s) 4 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media prefer BIIB or ALNY?

In the previous week, Biogen had 9 more articles in the media than Alnylam Pharmaceuticals. MarketBeat recorded 33 mentions for Biogen and 24 mentions for Alnylam Pharmaceuticals. Biogen's average media sentiment score of 0.93 beat Alnylam Pharmaceuticals' score of 0.37 indicating that Biogen is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Biogen 18 Very Positive mention(s) 4 Positive mention(s) 6 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Positive Alnylam Pharmaceuticals 6 Very Positive mention(s) 1 Positive mention(s) 9 Neutral mention(s) 4 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media favor ALNY or UTHR?

In the previous week, Alnylam Pharmaceuticals had 1 more articles in the media than United Therapeutics. MarketBeat recorded 24 mentions for Alnylam Pharmaceuticals and 23 mentions for United Therapeutics. United Therapeutics' average media sentiment score of 0.82 beat Alnylam Pharmaceuticals' score of 0.37 indicating that United Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alnylam Pharmaceuticals 6 Very Positive mention(s) 1 Positive mention(s) 9 Neutral mention(s) 4 Negative mention(s) 1 Very Negative mention(s) Neutral United Therapeutics 13 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Alnylam Pharmaceuticals (ALNY) Competitors

$288.06 -10.70 (-3.58%)

Closing price 07/13/2026 04:00 PM Eastern

Extended Trading

$287.19 -0.87 (-0.30%)

As of 04:04 AM Eastern

Compare

ALNY vs. GILD, VRTX, REGN, BIIB, and UTHR

Should you buy Alnylam Pharmaceuticals stock or one of its competitors? MarketBeat compares Alnylam Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Alnylam Pharmaceuticals include Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), and United Therapeutics (UTHR). These companies are all part of the "biotechnology" industry.

How does Alnylam Pharmaceuticals compare to Gilead Sciences?

Alnylam Pharmaceuticals (NASDAQ:ALNY) and Gilead Sciences (NASDAQ:GILD) are both large-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, risk, profitability, dividends, earnings, analyst recommendations and media sentiment.

Alnylam Pharmaceuticals has a beta of 0.27, meaning that its stock price is 73% less volatile than the broader market. Comparatively, Gilead Sciences has a beta of 0.32, meaning that its stock price is 68% less volatile than the broader market.

Gilead Sciences has higher revenue and earnings than Alnylam Pharmaceuticals. Gilead Sciences is trading at a lower price-to-earnings ratio than Alnylam Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alnylam Pharmaceuticals	$3.71B	10.36	$313.75M	$3.66	78.70
Gilead Sciences	$29.44B	5.54	$8.51B	$7.34	17.90

93.0% of Alnylam Pharmaceuticals shares are owned by institutional investors. Comparatively, 83.7% of Gilead Sciences shares are owned by institutional investors. 0.9% of Alnylam Pharmaceuticals shares are owned by insiders. Comparatively, 0.3% of Gilead Sciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

In the previous week, Gilead Sciences had 12 more articles in the media than Alnylam Pharmaceuticals. MarketBeat recorded 36 mentions for Gilead Sciences and 24 mentions for Alnylam Pharmaceuticals. Gilead Sciences' average media sentiment score of 0.86 beat Alnylam Pharmaceuticals' score of 0.37 indicating that Gilead Sciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alnylam Pharmaceuticals	6 Very Positive mention(s)	1 Positive mention(s)	9 Neutral mention(s)	4 Negative mention(s)	1 Very Negative mention(s)	Neutral
Gilead Sciences	22 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	5 Negative mention(s)	0 Very Negative mention(s)	Positive

Gilead Sciences has a net margin of 30.99% compared to Alnylam Pharmaceuticals' net margin of 11.72%. Alnylam Pharmaceuticals' return on equity of 85.76% beat Gilead Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alnylam Pharmaceuticals	11.72%	85.76%	10.32%
Gilead Sciences	30.99%	48.19%	18.28%

Alnylam Pharmaceuticals currently has a consensus target price of $457.57, indicating a potential upside of 58.84%. Gilead Sciences has a consensus target price of $159.04, indicating a potential upside of 21.03%. Given Alnylam Pharmaceuticals' higher probable upside, research analysts clearly believe Alnylam Pharmaceuticals is more favorable than Gilead Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alnylam Pharmaceuticals	0 Sell rating(s)	6 Hold rating(s)	18 Buy rating(s)	2 Strong Buy rating(s)	2.85
Gilead Sciences	0 Sell rating(s)	3 Hold rating(s)	26 Buy rating(s)	0 Strong Buy rating(s)	2.90

Summary

Gilead Sciences beats Alnylam Pharmaceuticals on 10 of the 17 factors compared between the two stocks.

How does Alnylam Pharmaceuticals compare to Vertex Pharmaceuticals?

Vertex Pharmaceuticals (NASDAQ:VRTX) and Alnylam Pharmaceuticals (NASDAQ:ALNY) are both large-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, valuation, profitability, earnings, analyst recommendations, media sentiment, institutional ownership and dividends.

91.0% of Vertex Pharmaceuticals shares are owned by institutional investors. Comparatively, 93.0% of Alnylam Pharmaceuticals shares are owned by institutional investors. 0.2% of Vertex Pharmaceuticals shares are owned by company insiders. Comparatively, 0.9% of Alnylam Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Vertex Pharmaceuticals has higher revenue and earnings than Alnylam Pharmaceuticals. Vertex Pharmaceuticals is trading at a lower price-to-earnings ratio than Alnylam Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vertex Pharmaceuticals	$12.00B	10.16	$3.95B	$16.86	28.48
Alnylam Pharmaceuticals	$3.71B	10.36	$313.75M	$3.66	78.70

In the previous week, Vertex Pharmaceuticals had 32 more articles in the media than Alnylam Pharmaceuticals. MarketBeat recorded 56 mentions for Vertex Pharmaceuticals and 24 mentions for Alnylam Pharmaceuticals. Vertex Pharmaceuticals' average media sentiment score of 0.80 beat Alnylam Pharmaceuticals' score of 0.37 indicating that Vertex Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vertex Pharmaceuticals	31 Very Positive mention(s)	10 Positive mention(s)	12 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Alnylam Pharmaceuticals	6 Very Positive mention(s)	1 Positive mention(s)	9 Neutral mention(s)	4 Negative mention(s)	1 Very Negative mention(s)	Neutral

Vertex Pharmaceuticals has a net margin of 35.51% compared to Alnylam Pharmaceuticals' net margin of 11.72%. Alnylam Pharmaceuticals' return on equity of 85.76% beat Vertex Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vertex Pharmaceuticals	35.51%	23.86%	17.13%
Alnylam Pharmaceuticals	11.72%	85.76%	10.32%

Vertex Pharmaceuticals presently has a consensus price target of $559.61, suggesting a potential upside of 16.52%. Alnylam Pharmaceuticals has a consensus price target of $457.57, suggesting a potential upside of 58.84%. Given Alnylam Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Alnylam Pharmaceuticals is more favorable than Vertex Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vertex Pharmaceuticals	0 Sell rating(s)	4 Hold rating(s)	21 Buy rating(s)	0 Strong Buy rating(s)	2.84
Alnylam Pharmaceuticals	0 Sell rating(s)	6 Hold rating(s)	18 Buy rating(s)	2 Strong Buy rating(s)	2.85

Vertex Pharmaceuticals has a beta of 0.29, meaning that its stock price is 71% less volatile than the broader market. Comparatively, Alnylam Pharmaceuticals has a beta of 0.27, meaning that its stock price is 73% less volatile than the broader market.

Summary

Vertex Pharmaceuticals beats Alnylam Pharmaceuticals on 9 of the 17 factors compared between the two stocks.

How does Alnylam Pharmaceuticals compare to Regeneron Pharmaceuticals?

Regeneron Pharmaceuticals (NASDAQ:REGN) and Alnylam Pharmaceuticals (NASDAQ:ALNY) are both large-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, dividends, profitability, media sentiment, valuation, institutional ownership, earnings and analyst recommendations.

In the previous week, Regeneron Pharmaceuticals had 6 more articles in the media than Alnylam Pharmaceuticals. MarketBeat recorded 30 mentions for Regeneron Pharmaceuticals and 24 mentions for Alnylam Pharmaceuticals. Regeneron Pharmaceuticals' average media sentiment score of 0.44 beat Alnylam Pharmaceuticals' score of 0.37 indicating that Regeneron Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Regeneron Pharmaceuticals	11 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	5 Negative mention(s)	0 Very Negative mention(s)	Neutral
Alnylam Pharmaceuticals	6 Very Positive mention(s)	1 Positive mention(s)	9 Neutral mention(s)	4 Negative mention(s)	1 Very Negative mention(s)	Neutral

Regeneron Pharmaceuticals has a beta of 0.24, suggesting that its stock price is 76% less volatile than the broader market. Comparatively, Alnylam Pharmaceuticals has a beta of 0.27, suggesting that its stock price is 73% less volatile than the broader market.

Regeneron Pharmaceuticals has higher revenue and earnings than Alnylam Pharmaceuticals. Regeneron Pharmaceuticals is trading at a lower price-to-earnings ratio than Alnylam Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Regeneron Pharmaceuticals	$14.34B	4.89	$4.50B	$41.04	16.16
Alnylam Pharmaceuticals	$3.71B	10.36	$313.75M	$3.66	78.70

83.3% of Regeneron Pharmaceuticals shares are owned by institutional investors. Comparatively, 93.0% of Alnylam Pharmaceuticals shares are owned by institutional investors. 7.0% of Regeneron Pharmaceuticals shares are owned by insiders. Comparatively, 0.9% of Alnylam Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Regeneron Pharmaceuticals has a net margin of 29.65% compared to Alnylam Pharmaceuticals' net margin of 11.72%. Alnylam Pharmaceuticals' return on equity of 85.76% beat Regeneron Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Regeneron Pharmaceuticals	29.65%	13.16%	10.17%
Alnylam Pharmaceuticals	11.72%	85.76%	10.32%

Regeneron Pharmaceuticals currently has a consensus target price of $787.67, indicating a potential upside of 18.79%. Alnylam Pharmaceuticals has a consensus target price of $457.57, indicating a potential upside of 58.84%. Given Alnylam Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Alnylam Pharmaceuticals is more favorable than Regeneron Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Regeneron Pharmaceuticals	0 Sell rating(s)	9 Hold rating(s)	17 Buy rating(s)	1 Strong Buy rating(s)	2.70
Alnylam Pharmaceuticals	0 Sell rating(s)	6 Hold rating(s)	18 Buy rating(s)	2 Strong Buy rating(s)	2.85

Summary

Alnylam Pharmaceuticals beats Regeneron Pharmaceuticals on 10 of the 17 factors compared between the two stocks.

How does Alnylam Pharmaceuticals compare to Biogen?

Biogen (NASDAQ:BIIB) and Alnylam Pharmaceuticals (NASDAQ:ALNY) are both large-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, media sentiment, dividends, valuation, risk, institutional ownership, analyst recommendations and earnings.

Biogen has higher revenue and earnings than Alnylam Pharmaceuticals. Biogen is trading at a lower price-to-earnings ratio than Alnylam Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biogen	$9.89B	3.12	$1.29B	$9.32	22.43
Alnylam Pharmaceuticals	$3.71B	10.36	$313.75M	$3.66	78.70

In the previous week, Biogen had 9 more articles in the media than Alnylam Pharmaceuticals. MarketBeat recorded 33 mentions for Biogen and 24 mentions for Alnylam Pharmaceuticals. Biogen's average media sentiment score of 0.93 beat Alnylam Pharmaceuticals' score of 0.37 indicating that Biogen is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Biogen	18 Very Positive mention(s)	4 Positive mention(s)	6 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Positive
Alnylam Pharmaceuticals	6 Very Positive mention(s)	1 Positive mention(s)	9 Neutral mention(s)	4 Negative mention(s)	1 Very Negative mention(s)	Neutral

87.9% of Biogen shares are held by institutional investors. Comparatively, 93.0% of Alnylam Pharmaceuticals shares are held by institutional investors. 0.3% of Biogen shares are held by company insiders. Comparatively, 0.9% of Alnylam Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Biogen has a beta of 0.16, meaning that its stock price is 84% less volatile than the broader market. Comparatively, Alnylam Pharmaceuticals has a beta of 0.27, meaning that its stock price is 73% less volatile than the broader market.

Biogen has a net margin of 13.81% compared to Alnylam Pharmaceuticals' net margin of 11.72%. Alnylam Pharmaceuticals' return on equity of 85.76% beat Biogen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biogen	13.81%	12.83%	8.01%
Alnylam Pharmaceuticals	11.72%	85.76%	10.32%

Biogen currently has a consensus target price of $220.04, suggesting a potential upside of 5.27%. Alnylam Pharmaceuticals has a consensus target price of $457.57, suggesting a potential upside of 58.84%. Given Alnylam Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Alnylam Pharmaceuticals is more favorable than Biogen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biogen	2 Sell rating(s)	11 Hold rating(s)	17 Buy rating(s)	1 Strong Buy rating(s)	2.55
Alnylam Pharmaceuticals	0 Sell rating(s)	6 Hold rating(s)	18 Buy rating(s)	2 Strong Buy rating(s)	2.85

Summary

Alnylam Pharmaceuticals beats Biogen on 11 of the 17 factors compared between the two stocks.

How does Alnylam Pharmaceuticals compare to United Therapeutics?

Alnylam Pharmaceuticals (NASDAQ:ALNY) and United Therapeutics (NASDAQ:UTHR) are both large-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, risk, profitability, media sentiment, dividends, valuation and earnings.

United Therapeutics has a net margin of 40.62% compared to Alnylam Pharmaceuticals' net margin of 11.72%. Alnylam Pharmaceuticals' return on equity of 85.76% beat United Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alnylam Pharmaceuticals	11.72%	85.76%	10.32%
United Therapeutics	40.62%	19.24%	17.25%

Alnylam Pharmaceuticals presently has a consensus target price of $457.57, indicating a potential upside of 58.84%. United Therapeutics has a consensus target price of $644.82, indicating a potential upside of 20.40%. Given Alnylam Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts plainly believe Alnylam Pharmaceuticals is more favorable than United Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alnylam Pharmaceuticals	0 Sell rating(s)	6 Hold rating(s)	18 Buy rating(s)	2 Strong Buy rating(s)	2.85
United Therapeutics	0 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.83

93.0% of Alnylam Pharmaceuticals shares are owned by institutional investors. Comparatively, 94.1% of United Therapeutics shares are owned by institutional investors. 0.9% of Alnylam Pharmaceuticals shares are owned by company insiders. Comparatively, 8.6% of United Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, Alnylam Pharmaceuticals had 1 more articles in the media than United Therapeutics. MarketBeat recorded 24 mentions for Alnylam Pharmaceuticals and 23 mentions for United Therapeutics. United Therapeutics' average media sentiment score of 0.82 beat Alnylam Pharmaceuticals' score of 0.37 indicating that United Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alnylam Pharmaceuticals	6 Very Positive mention(s)	1 Positive mention(s)	9 Neutral mention(s)	4 Negative mention(s)	1 Very Negative mention(s)	Neutral
United Therapeutics	13 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Alnylam Pharmaceuticals has a beta of 0.27, meaning that its share price is 73% less volatile than the broader market. Comparatively, United Therapeutics has a beta of 0.58, meaning that its share price is 42% less volatile than the broader market.

United Therapeutics has lower revenue, but higher earnings than Alnylam Pharmaceuticals. United Therapeutics is trading at a lower price-to-earnings ratio than Alnylam Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alnylam Pharmaceuticals	$3.71B	10.36	$313.75M	$3.66	78.70
United Therapeutics	$3.18B	7.14	$1.33B	$27.09	19.77

Summary

Alnylam Pharmaceuticals beats United Therapeutics on 9 of the 17 factors compared between the two stocks.

Get Alnylam Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ALNY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ALNY vs. The Competition

Export

Metric	Alnylam Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$39.89B	$3.71B	$7.05B	$12.61B
Dividend Yield	N/A	2.20%	2.68%	8.00%
P/E Ratio	78.70	20.85	27.11	24.26
Price / Sales	10.36	314.01	589.14	117.88
Price / Cash	106.85	61.98	29.22	49.36
Price / Book	48.25	8.49	10.75	6.29
Net Income	$313.75M	$23.83M	$3.58B	$330.66M
7 Day Performance	-10.43%	-3.56%	-2.10%	-1.35%
1 Month Performance	1.84%	6.31%	3.29%	-0.64%
1 Year Performance	-8.77%	48.30%	26.32%	19.08%

Alnylam Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ALNY Alnylam Pharmaceuticals	4.0996 of 5 stars	$288.06 -3.6%	$457.57 +58.8%	-8.5%	$39.89B	$3.71B	78.70	2,770	Analyst Forecast
GILD Gilead Sciences	4.7993 of 5 stars	$129.61 -1.3%	$158.41 +22.2%	+19.8%	$162.98B	$29.44B	17.66	17,000	Analyst Upgrade
VRTX Vertex Pharmaceuticals	3.9177 of 5 stars	$529.59 +0.3%	$555.91 +5.0%	+2.4%	$134.02B	$12.00B	31.41	6,400	Analyst Forecast
REGN Regeneron Pharmaceuticals	4.6643 of 5 stars	$649.81 -0.7%	$817.65 +25.8%	+16.8%	$69.17B	$14.34B	15.83	15,410
BIIB Biogen	3.4456 of 5 stars	$208.46 -3.5%	$217.67 +4.4%	+55.7%	$31.91B	$9.89B	22.37	7,500	Trending News Analyst Upgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ALNY) was last updated on 7/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Alnylam Pharmaceuticals (ALNY) Competitors

ALNY vs. GILD, VRTX, REGN, BIIB, and UTHR

How does Alnylam Pharmaceuticals compare to Gilead Sciences?

Summary

How does Alnylam Pharmaceuticals compare to Vertex Pharmaceuticals?

Summary

How does Alnylam Pharmaceuticals compare to Regeneron Pharmaceuticals?

Summary

How does Alnylam Pharmaceuticals compare to Biogen?

Summary

How does Alnylam Pharmaceuticals compare to United Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALNY vs. The Competition

Alnylam Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Alnylam Pharmaceuticals (ALNY) Competitors

ALNY vs. GILD, VRTX, REGN, BIIB, and UTHR

How does Alnylam Pharmaceuticals compare to Gilead Sciences?

Which has more risk & volatility, ALNY or GILD?

Which has stronger earnings and valuation, ALNY or GILD?

Do insiders and institutionals believe in ALNY or GILD?

Does the media refer more to ALNY or GILD?

Is ALNY or GILD more profitable?

Do analysts recommend ALNY or GILD?

Summary

How does Alnylam Pharmaceuticals compare to Vertex Pharmaceuticals?

Do institutionals & insiders hold more shares of VRTX or ALNY?

Which has better earnings and valuation, VRTX or ALNY?

Does the media favor VRTX or ALNY?

Is VRTX or ALNY more profitable?

Do analysts rate VRTX or ALNY?

Which has more risk and volatility, VRTX or ALNY?

Summary

How does Alnylam Pharmaceuticals compare to Regeneron Pharmaceuticals?

Does the media prefer REGN or ALNY?

Which has more risk and volatility, REGN or ALNY?

Which has preferable valuation and earnings, REGN or ALNY?

Do insiders and institutionals have more ownership in REGN or ALNY?

Is REGN or ALNY more profitable?

Do analysts rate REGN or ALNY?

Summary

How does Alnylam Pharmaceuticals compare to Biogen?

Which has stronger earnings & valuation, BIIB or ALNY?

Does the media prefer BIIB or ALNY?

Do institutionals and insiders have more ownership in BIIB or ALNY?

Which has more risk & volatility, BIIB or ALNY?

Is BIIB or ALNY more profitable?

Do analysts rate BIIB or ALNY?

Summary

How does Alnylam Pharmaceuticals compare to United Therapeutics?

Is ALNY or UTHR more profitable?

Do analysts recommend ALNY or UTHR?

Do institutionals & insiders believe in ALNY or UTHR?

Does the media favor ALNY or UTHR?

Which has more risk and volatility, ALNY or UTHR?

Which has better earnings & valuation, ALNY or UTHR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALNY vs. The Competition

Alnylam Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools